MedTrace Logo

Genomics in Michigan Impacting Observation or Radiation

NCT02783950 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 356

Last updated 2024-09-26

Study results available
· View outcomes & findings →

Summary

To determine the impact of Decipher test results on adjuvant treatment decisions of high-risk post-RP patients with undetectable post-op prostate specific antigen (PSA) compared to clinical factors alone.

Conditions

Interventions

OTHER

Decipher Prostate Cancer Classifier

The Decipher test (GenomeDx Biosciences, San Diego, CA) is a genomic test that predicts high grade disease, the probability of metastasis and prostate cancer-specific mortality for men with prostate cancer.

Sponsors & Collaborators

  • Michigan Urological Surgery Improvement Collaborative (MUSIC)

    collaborator OTHER

  • GenomeDx Biosciences Corp

    collaborator INDUSTRY

  • University of Michigan Rogel Cancer Center

    lead OTHER

Principal Investigators

  • Todd Morgan, MD · University of Michigan

  • Michael Cher, MD · Wayne State University

Study Design

Allocation
RANDOMIZED
Purpose
DIAGNOSTIC
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-01-17
Primary Completion
2020-02-01
Completion
2024-04-02

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02783950 on ClinicalTrials.gov